SUBSCRIBE

Breaking News on Contract Research, Manufacturing & Clinical Trials

Headlines > Commercial Services

Read more breaking news

 

 
Update

DSM launches InnoSyn route scouting service for process R&D

By Alexandria Pesic , 07-Sep-2010
Last updated on 07-Sep-2010 at 15:46 GMT

DSM Pharma Chemicals, a business unit of DSM Pharmaceutical Products, has announced the launch of InnoSyn route scouting services, meeting pharma needs to outsource process development R&D.

In response to increasing numbers of customers expressing interest in outsourcing the research and development of reliable, cost-effective manufacturing processes, DSM has launched InnoSyn route scouting services.

The concept behind this is to provide customers with a “cost efficient, greener and more convergent way to manufacturing [with] shorter, more sustainable manufacturing processes,” Ronald Gebhard R&D director of DSM Pharmaceutical Products told Outsourcing-pharma.

He explained that the manufacturing services offered by InnoSyn are unique to DSM, adding that the company has access to a wide variety of technologies which combine both biochemical and traditional chemical approaches.

This, he suggested, enables the company to “take an unbiased look at the molecule and find the best option for our customer.”

This sentiment was echoed by Oliver May, Business Manager of InnoSyn, who said: Due to the reduced focus and resources in process R&D within our customers' operations there is an increasing demand for developing flexible and robust 'technology packages' ready to implement at large scale.

“The new DSM InnoSyn route scouting services are setup to address exactly this specific need based on DSM's broad and unique technology toolbox.”

The InnoSyn service will be operated by DSM’s custom manufacturing arm that already provides a range of process efficiency boosting enzymes such as pharmaPLE, lyases, transaminases, dehydrogenases and homogeneous catalysts for asymmetric hydrogenations, aromatic substitutions, and oxidations.

In other DSM news, the microbial fermentation CMO business unit, along with biopharmaceutical company, PolyTherics Limited, today announced a joint agreement for the process development and manufacture of PolyTherics’ biobetter product, HiPEG IFN alpha-2a.